Plan B distributor not optimistic about approval

05/5/2004 | Washington Post, The

The president of Barr Laboratories' research division said she does not expect the FDA to switch the controversial morning-after contraceptive from prescription to over-the-counter status because of a lack of communication with the government agency. She said the drug company is still hopeful the agency, whose advisory committee overwhelmingly voted for the switch, would grant an "approvable letter" to allow Barr to make the switch in the future once certain conditions are met.

View Full Article in:

Washington Post, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID